A clinical study to evaluate the efficacy of degarelix in prostate cancer patients

A clinical study to evaluate the efficacy of degarelix in prostate cancer patients - A clinical study to evaluate the efficacy of degarelix in prostate cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015128

Enrollment

Registered

2014-09-12

Start date

2014-08-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

degarelix

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Adenocarcinoma of the prostate histologically confirmed Progressive Prostate cancer based on PSA criteria Stable medical condition, including the absence of severe hepatological, cardiac renal and hematological disorder etc

Exclusion criteria

Exclusion criteria: Uncontroled general complication. etc

Design outcomes

Primary

Measure	Time frame
PSA response rate	—

Secondary

Measure	Time frame
FSH level urinary symptoms	—

Countries

Japan

Contacts

Public ContactTakeo Kosaka

Keio University School of Medicine Department of Urology

takemduro@a6.keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026